Drug Trial Radar · NCT03004248
Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar Lines
Last checked: Nov 20, 2026Latest source record: Jul 13, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,691
Actual
Start
Dec 9, 2016
Primary completion
Oct 17, 2018
Study completion Oct 17, 2018
Sponsor
- Lead sponsor
- Revance Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 28, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a long term safety study of DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar lines following single and repeat administration.
Conditions
- Glabellar Frown Lines
Interventions
Botulinum Toxins, Type ABiological
Intramuscular Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment Emergent Adverse Events (TEAE)Time frame: 0-36 weeks
Locations
61 sites in 2 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Beverly Hills, California
Site not named
Encinitas, California
Site not named
Fremont, California
Site not named
Los Angeles, California
Site not named
Manhattan Beach, California
Site not named
Newport Beach, California
Site not named
Roseville, California
Site not named
Sacramento, California
Site not named
San Diego, California
Site not named
San Diego, California
Site not named
San Francisco, California
Site not named
Santa Monica, California
Site not named
Greenwood Village, Colorado
Site not named
Washington D.C., District of Columbia
Site not named
Washington D.C., District of Columbia
Site not named
Boca Raton, Florida
Site not named
Bradenton, Florida
Site not named
Coral Gables, Florida
Site not named
Miami, Florida
Site not named
West Palm Beach, Florida
Site not named
Chicago, Illinois
Site not named
Lincolnshire, Illinois
Site not named
Naperville, Illinois
Site not named
New Orleans, Louisiana
Site not named
New Orleans, Louisiana
Site not named
Baltimore, Maryland
Site not named
Glenn Dale, Maryland
Site not named
Hunt Valley, Maryland
Site not named
Rockville, Maryland
Site not named
Chestnut Hill, Massachusetts
Site not named
Birmingham, Michigan
Site not named
Fridley, Minnesota
Site not named
St Louis, Missouri
Site not named
Omaha, Nebraska
Site not named
Montclair, New Jersey
Site not named
New York, New York
Site not named
New York, New York
Site not named
New York, New York
Site not named
New York, New York
Showing 40 of 61 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.